Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939692 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions
A Phase 1 study, sponsored by Torrent Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00939692: Completed Phase 1 study, sponsored by Torrent Pharmaceuticals Limited.
NCT00939692 is a Phase 1 study that has completed, run by Torrent Pharmaceuticals Limited. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939692, a Phase 1 study, has completed, sponsored by Torrent Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
* Objective: * Compare the bioequivalence of a test topiramate formulation (Torrent Pharmaceuticals Limited) to an equivalent oral dose of the commercially available topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.) in a test population of 26 adult subjects under fasted conditions. * Clinical Design: * Studies were Randomized, Two-Way Crossover, Single-Dose,Open-Label in healthy human adult subjects.
Interventions
- DRUG Topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939692
The ClinicalTrials.gov registry entry for NCT00939692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Torrent Pharmaceuticals Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topiramate is the first listed.
NCT00939692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00939692 about?
NCT00939692 is a clinical study titled "Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions". * Objective: * Compare the bioequivalence of a test topiramate formulation (Torrent Pharmaceuticals Limited) to an equivalent oral dose of the commercially available topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.) in a test population of 26 adult subjects under fasted conditions. * Clinical...
What is the current status of trial NCT00939692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2007-01. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00939692?
The interventions under investigation include: Topiramate (DRUG).
Who is sponsoring clinical trial NCT00939692?
This trial is sponsored by Torrent Pharmaceuticals Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.